Meeting
2016 Genitourinary Cancers Symposium
Interrogating metastatic prostate cancer treatment switch decisions.
Authors
David Lorente
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
David Lorente , Praful Ravi , Niven Mehra , Carmel Jo Pezaro , Aurelius Gabriel Omlin , Miguel Miranda , Heather Payne , Emma Hall , Leon W M M Terstappen , Maarten J Ijzerman , Johann S. De Bono
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 296)
DOI
10.1200/jco.2016.34.2_suppl.296
Abstract #
296
Poster Bd #
N1
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Gene expression in circulating tumor cells (CTC) and plasma androgen receptor (AR) gene copy number (CN) for castration-resistant prostate cancer (CRPC) patients (pts) treated with cabazitaxel.
First Author: Giorgia Gurioli
Poster
2017 Genitourinary Cancers Symposium
AR nuclear localization and microtubule bundling as markers of docetaxel and cabazitaxel sensitivity in metastatic castration-resistant prostate cancer (mCRPC): Prospective biomarker analysis from TAXYNERGY.
First Author: Paraskevi Giannakakou
Poster
2014 Genitourinary Cancers Symposium
Relationship of bone scan index and progression-free survival after docetaxel treatment for CRPC patients with bone metastases.
First Author: Atsushi Mizokami
Poster
2013 ASCO Annual Meeting
TAXYNERGY (NCT01718353): A randomized phase II trial examining an early switch from first-line docetaxel to cabazitaxel, or cabazitaxel to docetaxel, in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Emmanuel S. Antonarakis